Schneider, Rebekka KZiegler, SusanneLeisten, IsabelleFerreira, Monica SVSchumacher, AnneRath, BjörnFahrenkamp, DirkMüller-Newen, GerhardCrysandt, MartinaWilop, StefanJost, EdgarKoschmieder, SteffenKnüchel, RuthBrümmendorf, Tim HZiegler, Patrick2015-01-052014Schneider, R. K., S. Ziegler, I. Leisten, M. S. Ferreira, A. Schumacher, B. Rath, D. Fahrenkamp, et al. 2014. “Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms.” Journal of Hematology & Oncology 7 (1): 92. doi:10.1186/s13045-014-0092-2. http://dx.doi.org/10.1186/s13045-014-0092-2.1756-8722http://nrs.harvard.edu/urn-3:HUL.InstRepos:13581222We characterized bone marrow stromal cells (BMSC) from patients with pre-fibrotic myeloproliferative neoplasms (MPN). MPN-BMSC showed decreased capacity to stimulate the proliferation of colony-forming units of normal hematopoietic stem and progenitor cells and displayed increased matrix remodelling (in particular fibronectin deposition) compared to control BMSC. This finding was confirmed in pre-fibrotic MPN bone marrow biopsies in a tissue microarray (n = 34), which stained positive for fibronectin in the absence of reticulin as a standard myelofibrosis marker. Fibronectin expression correlated significantly with reduced haemoglobin levels in MPN-patients (p = 0.007; R2 = 0.42). Our data show significant cell-intrinsic alterations in MPN-MSC and suggest that Fibronectin expression might be applicable as a biomarker for the identification of early myelofibrotic transformation in reticulin-negative MPN.en-USMyeloproliferative neoplasmsMyelofibrosisMesenchymal stromal cellsTissue microarray biomarkerFibronectinJournal Article2015-01-0510.1186/s13045-014-0092-2